Navigation Links
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
Date:4/29/2013

NEW YORK, April 29, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of PROLOR Biotech, Inc. ("PROLOR" or the "Company") (NYSE MKT: PBTH) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to OPKO Health, Inc. ("OPKO") (NYSE: OPK).

(Logo:  http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Click here to learn more about the investigation http://zlk.9nl.com/prolor-biotech-pbth/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, PROLOR shareholders may elect to receive 0.9951 shares of OPKO for each share of PROLOR they own, representing a value of approximately $7.025 per share. The transaction has a total approximate value of $480 million. The investigation concerns whether the PROLOR Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the transaction, and whether OPKO is underpaying for PROLOR stock, thus unlawfully harming PROLOR stockholders. In particular, at least one analyst set a price target for PROLOR  stock at $12.00 per share.

If you own common stock in PROLOR and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/prolor-biotech-pbth/

Levi & Korsinsky is a national firm with offices in New York, New Jersey and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
2. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
3. Hadasit Bio-Holdings CEO Letter to Shareholders
4. Medifirst Solutions, Inc. Announces Further Update To Shareholders
5. Letter from Alliqua CEO, Dave Johnston, to Shareholders
6. TPI to Hold 2012 Shareholder Annual Meeting on May 8, 2013 In New York City
7. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
8. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
9. Amarantus BioSciences Issues CEO Letter to Shareholders
10. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
11. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots ... scientists from around the world, was today awarded the "Best Science & Technology ... entirely on merit and decided upon by a dedicated team of researchers and ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
(Date:1/18/2017)... According to a new market research report "In situ ... & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast ... Million by 2021 from USD 557.1 Million in 2016, growing at a CAGR ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
Breaking Biology Technology:
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions ... Identity management products and solutions and a cutting-edge ... today that it is offering seamless, integrated solutions ... security entrance products. The solutions provide IdentyTech,s customers ... secure their facilities from crime and theft. ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
Breaking Biology News(10 mins):